Intratumoral IL-12 and TNF-α-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity

Annals of Surgical Oncology

Volumn 11, Issue 2, 2004, Pages 147-156

  Sabel, Michael S ^a,e   Skitzki, Joseph ^a   Stoolman, Lloyd ^b   Egilmez, Nejat K ^c   Mathiowitz, Edith ^d   Bailey, Nicola ^d   Chang, Wen Jian ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; IL 12; Immunotherapy; Microspheres; TNF

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MICROSPHERE; MONOCLONAL ANTIBODY CD3; POLYLACTIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; ENCAPSULATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; IMMUNE RESPONSE; LYMPH NODE; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PROTEIN SECRETION; SPLEEN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; ADJUVANT THERAPY; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; EVALUATION; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICROSPHERES; NEOADJUVANT THERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342617508     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.03.022     Document Type: Article

References (33)

1. Riethmuller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol 1992;4:647-55.
2. Brown DC, Purushotham AD, Birnie GD, George WD. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery 1995;117:96-101.
3. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Oncol 2000;18: 80-6.
4. Ghadersohi A, Chitta K, Greco WR, et al. Tumor antigens and markers for breast and ovarian cancers. Frontiers in Bioscience 2002;7:e48-57.
5. Mastrangelo MJ, Sato T, Lattime EC, et al. Cellular vaccine therapies for cancer. Cancer Treat Res 1998;94:35-50.
6. Egilmez NK, Jong YS, Sabel MS, et al. In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000;60:3832-7.
7. Sabel MS, Hill HC, Jong YS, et al. Neoadjuvant therapy with interleukin-12 loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 2001;130:470-8.
8. Margaretten NC, Witschi H. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung. Cancer Res 1988;48:2779-83.
9. Aruga E, Aruga A, Area MJ, et al. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, IL-12 or GM-CSF. Cancer Gene Therapy 1997;4:157-66.
10. Wiltrout RH, Matheison BJ, Back TC, Salup RR. Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy. Progr Clin Biol Res 1987;244:17-25.
11. Yuhas JM, Pazmino NH, Proctor JO, Toya RE. A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor. Cancer Res 1974;34: 722-8.
12. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386:410-4.
13. Yoshizawa H, Sakai K, Chang AE, Shu S. Activation of anti-CD3 of tumor draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991;134:473-9.
14. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and an reappraisal. Hum Gene Ther 2000;11:1269-75.
15. Hill HC, Conway TF Jr, Sabel MS, et al. Cancer Immunotherapy with interleukin-12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2003;62:7254-63.
16. Burke F. Cytokines (FFNs, TNF-alpha, FL-2, and IL-12) and animal models of cancer. Cytokines Cell Mol Ther 1999;5:51-61.
17. Hendrzak JA, Brunda MJ. Antitumor and antimetastatic activity of interleukin 12. Curr Top Microbiol Immunol 1996;213:65-83.
18. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exper Med 1993;178:1223-30.
19. Brunda MJ, Luistro L, Rumennik L, et al. Interluekin-12: murine models of a potent antitumor agent. Ann NY Acad Sci 1996;795: 266-74.
20. Reference deleted.
21. Smyth MJ, Taniguchi M, Street SEA. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunology 2000;165:2665-70.
22. Gee MS, Koch CJ, Evans SM, et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999;59:4882-9.
23. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
24. Aruga A, Tanigawa K, Aruga E, et al. Enhanced adjuvant effect of granulocyte-macrophage colony stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Cancer Gene Therapy 1999;6:89-95.
25. Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Intern Immunol 2001;13:897-908.
26. Lasek W, Feleszko W, Golab J, et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 1997;45: 100-8.
27. Lasek W, Mackiewicz A, Czajka A, et al. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther 2000;7:1581-90.
28. Zagozdzon R, Stoklosa T, Golab J, et al. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res 1997;17:4493-8.
29. Ahlers JD, Dunlop N, Ailing DW, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNF-a synergize with IL-12 to enhance induction of CTL. J Immunol 1997;158:3947-58.
30. Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19:1848-54.
31. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
32. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999;48:353-62.
33. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 2000;11:681-92.